Some or all of these could be by decreased by reducing the quantity of GLP-1 RAs in the outer circulation, and targeting them more to their natural receptors in the intestinal vagal afferents via oral delivery
247,248,249 However, these associations were not observed in non-European populations, underscoring potential ethnic differences in genetic susceptibility to hyperuricemia-related metabolic abnormalities
not necessarily related to need in any way
Animal studies show substantial evidence across stroke models (full functional recovery in spatial memory, motor coordination, balance), Parkinsons models (protection of dopaminergic neurons, near-complete prevention of mortality), multiple sclerosis models (significantly less brain damage), and traumatic brain injury (reduced hemorrhage and edema)
Glucagon-like peptide receptor agonists (GLP-1 RAs or GLP-1 agonists for short) are drugs manufactured to bind to GLP-1 receptors, essentially mimicking and magnifying the effects of these hormones
GIPR/GLP-1R dual agonist therapies for diabetes and weight losschemistry, physiology, and clinical applications